toxylact

The first professional lActological database in the word

Niperotidine (ATC A02BA05) is a withdrawn H2-receptor antagonist for peptic ulcer disease that carries a significant risk of severe hepatotoxicity and is considered unsuitable during breastfeeding. Its use in pregnancy and lactation should be avoided, with safer alternative H2-blockers or proton pump inhibitors preferred when acid suppression is required.

Drug class and indications

Niperotidine belongs to the class of histamine H2-receptor antagonists used to reduce gastric acid secretion. It was indicated for erosive esophagitis, short-term treatment of active duodenal and benign gastric ulcers, long-term prophylaxis of duodenal ulcers and gastric hypersecretory states, treatment of gastroesophageal reflux, prevention of upper GI bleeding in critically ill patients, adjunctive therapy in strong acid ingestions, and relief of heartburn (pyrosis).

Pharmacokinetics and dynamics

Niperotidine selectively blocks H2 receptors on gastric parietal cells, leading to reduced basal and meal-stimulated gastric acid secretion. It has an oral bioavailability of about 65%, a plasma half-life around 2.5 hours, and a clinical duration of action of approximately 6–7 hours after a single dose.

Toxicological profile and withdrawal

Post-marketing experience showed numerous cases of toxic hepatitis associated with niperotidine, including fatal outcomes, which led to its withdrawal from pharmaceutical markets. Hepatotoxicity appears to be idiosyncratic and severe, positioning niperotidine as a high-risk H2 antagonist compared with other agents in its class.

Other adverse effects and interactions

Beyond hepatotoxicity, niperotidine likely shares class adverse effects of H2-receptor antagonists such as headache, dizziness, confusion, gastrointestinal disturbances, and rarely hematologic toxicity and hypotension. It may interact with drugs requiring an acidic gastric environment for absorption (for example, atazanavir), leading to decreased serum concentrations and reduced efficacy.

Pregnancy toxicology

The local reference classifies niperotidine as pregnancy category X, indicating that risk clearly outweighs any potential benefit and that it should not be used during pregnancy. In contrast, other H2 antagonists (such as ranitidine historically, and now famotidine) have been used in pregnancy with substantially better safety profiles, and non-pharmacologic or antacid-based strategies should be preferred when possible.

Lactation risk assessment

The monograph categorizes niperotidine as toxico-lactation category IV, meaning it is not suitable for use during lactation. Although there are no direct lactation pharmacokinetic data for niperotidine, the combination of significant hepatotoxic potential and availability of better-studied H2 antagonists (famotidine, nizatidine) or PPIs with minimal milk transfer argues strongly against its use in breastfeeding women.

Clinical recommendations in breastfeeding

Given its withdrawal for safety reasons, niperotidine should be avoided entirely in breastfeeding patients, and breastfeeding-compatible alternatives should be selected. For management of heartburn or dyspepsia during lactation, non-pharmacologic measures and antacids or alginates are first-line; if acid suppression is needed, famotidine or nizatidine among H2 antagonists, or omeprazole/pantoprazole among PPIs, are preferred options.

Risk–benefit and monitoring considerations

Because safer and well-studied alternatives exist, any theoretical benefit of niperotidine is clearly outweighed by its hepatotoxicity risk in both pregnant and lactating women. In the rare event of legacy exposure, maternal liver function (transaminases, bilirubin, coagulation parameters) and clinical signs of hepatic injury should be closely monitored, and breastfeeding should be reassessed in light of maternal toxicity.

Recent ARTICLES

July 24

Abdominal Compartment Syndrome

PWhile the formal term and its consensus definitions were codified by the World Society of the Abdominal Compartment Syndrome (WSACS) only in the early 2000s, the physiological underpinnings have been observed for over 150 years. In 1863, the French physiologist Etienne-Jules Marey was the first to document the reciprocal relationship between intra-abdominal pressure (IAP) and respiratory function, noting that the expansion of the abdominal cavity directly impacted the efficiency of the thoracic bellows.

July 18

Assessment of Postoperative Fever

For the physician and the student of medicine, the assessment of postoperative fever is not merely a task of temperature monitoring, but a diagnostic journey that requires a nuanced understanding of immunology, physiology, and clinical timing. Guided by the principle of "Primum non nocere," this report seeks to bridge the gap between complex pathophysiological mechanisms and the empathetic care of the patient, providing a comprehensive framework for identifying, understanding, and managing this common clinical challenge.

July 14

Clinical Review of Congenital and Acquired Cystic Kidney Diseases

The healing arts, as envisioned by the ancient traditions of medicine, seek not merely the eradication of pathology but the restoration of a delicate equilibrium between the body’s internal environment and the external world. In the realm of nephrology, cystic diseases of the kidney represent a profound disruption of this balance.

Spotlight

A Comprehensive Analysis of Complement System Deficiencies in Pediatric and Adult Populations

The human immune system is a tapestry of ancient evolutionary mechanisms and highly specialized adaptive responses, woven together to maintain the delicate equilibrium of health. At the heart of this architecture lies the complement system, a complex network of over fifty proteins that function as the primordial vanguard of innate immunity. Named for its ability to "complement" the action of antibodies, this system serves as a bridge between the immediate, non-specific recognition of pathogens and the targeted, long-term memory of the adaptive immune response. However, when this sentinel falls silent due to genetic or acquired deficiencies, the result is a state of nuanced immunosuppression that significantly alters the human clinical landscape across all ages.